Cargando…

A digital method to interpret the C-MYC stain in diffuse large B cell lymphoma

Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) is a heterogenous group of aggressive lymphomas. C-MYC expression by immunohistochemical stain (IHC) is shown to be an independent prognostic factor in DLBCL. In the clinical setting, MYC stain is currently evaluated by manual quant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Balakrishna, Jayalakshmi, Kulewsky, Jesse, Parwani, Anil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576988/ https://www.ncbi.nlm.nih.gov/pubmed/36268094 http://dx.doi.org/10.1016/j.jpi.2022.100100

Ejemplares similares

Immunohistochemical Detection of MYC-driven Diffuse Large B-Cell Lymphomas
por: Kluk, Michael J., et al.
Publicado: (2012)

Copy Number Alteration and Mutational Profile of High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B-Cell Lymphoma with MYC-Rearrangement, and Diffuse Large B-Cell Lymphoma with MYC-Cluster Amplification
por: Miyaoka, Masashi, et al.
Publicado: (2022)

Diffuse Large B-Cell Lymphoma in Kenya: MYC, BCL2, and the Cell of Origin
por: Wawire, Jonathan, et al.
Publicado: (2019)

Artificial intelligence to detect MYC translocation in slides of diffuse large B-cell lymphoma
por: Swiderska-Chadaj, Zaneta, et al.
Publicado: (2020)

Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma
por: Kleo, Karsten, et al.
Publicado: (2019)

C-MYC Aberrations as Prognostic Factors in Diffuse Large B-cell Lymphoma: A Meta-Analysis of Epidemiological Studies
por: Zhou, Kuangguo, et al.
Publicado: (2014)

MYC Protein Expression in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
por: Gill, Kamraan Z., et al.
Publicado: (2014)

The prognosis of MYC translocation positive diffuse large B‐cell lymphoma depends on the second hit
por: Clipson, Alexandra, et al.
Publicado: (2015)

PB2377: PREDICTING CELL OF ORIGIN FROM DIGITIZED IMAGES OF HEMATOXYLIN AND EOSIN-STAINED SLIDES OF DIFFUSE LARGE B-CELL LYMPHOMAS USING A CELL-BASED DEEP-LEARNING MODEL
por: Yuce, Anil, et al.
Publicado: (2023)

New MYC IHC Classifier Integrating Quantitative Architecture Parameters to Predict MYC Gene Translocation in Diffuse Large B-Cell Lymphoma
por: Bigras, Gilbert, et al.
Publicado: (2018)

MYC overexpression but not MYC/BCL2 double expression predicts survival in bulky mass diffuse large B‐cell lymphoma patients
por: Wang, Yanjie, et al.
Publicado: (2023)

The Role of the MYC/miR-150/MYB/ZDHHC11 Network in Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma
por: Ziel-Swier, Lotteke J. Y. M., et al.
Publicado: (2022)

MYC Negative Rectal B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Burkitt's Lymphoma in an Immunocompetent Patient
por: Parikh, Jignesh G., et al.
Publicado: (2013)

Double-Expressor Phenotype (BCL-2/c-MYC Co-expression) of Diffuse Large B-Cell Lymphoma and Its Clinicopathological Correlation
por: Hashmi, Atif A, et al.
Publicado: (2021)

Increased MYC expression without MYC gene translocation in patients with the diffuse large B-cell-lymphoma subtype of iatrogenic immunodeficiency-associated lymphoproliferative disorders
por: Kabasawa, Nobuyuki, et al.
Publicado: (2021)

MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B‐cell lymphoma
por: Kawamoto, Keisuke, et al.
Publicado: (2016)

MYC-Positive Diffuse Large B-Cell Lymphoma in Leukemic Phase at Presentation: A Diagnostic and Therapeutic Challenge
por: Bilgin, Yavuz Memis, et al.
Publicado: (2021)

C-MYC and BCL2: Correlation between Protein Over-Expression and Gene Translocation and Impact on Outcome in Diffuse Large B Cell Lymphoma
por: Mohammed, Amrallah A, et al.
Publicado: (2019)

R-split-EPOCH plus high dose methotrexate in untreated diffuse large B cell lymphoma with MYC rearrangement or double expression of MYC and BCL-2
por: Sun, Peng, et al.
Publicado: (2021)

Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma
por: Ye, Qing, et al.
Publicado: (2015)

Combination of BCL-2 and MYC protein expression improves high-risk stratification in diffuse large B-cell lymphoma
por: Wang, Jing, et al.
Publicado: (2015)

MYC is a positive regulator of choline metabolism and impedes mitophagy-dependent necroptosis in diffuse large B-cell lymphoma
por: Xiong, J, et al.
Publicado: (2017)

Dose-adjusted EPOCH-R in patients with newly diagnosed diffuse large B-cell lymphoma harboring MYC rearrangement
por: Kojima, Minoru, et al.
Publicado: (2020)

Primary cutaneous diffuse large B‐cell lymphoma, leg type with MYC/BCL2/BCL6 overexpression
por: Okada, Yosuke, et al.
Publicado: (2021)

A retrospective study of MYC rearranged diffuse large B-cell lymphoma in the context of the new WHO and ICC classifications
por: El-Sharkawi, Dima, et al.
Publicado: (2023)

MYC Gene Rearrangements Are Closely Associated with Poor Survival of Diffuse Large B Cell Lymphoma with Hepatitis B Virus Infection
por: Liu, Zhihe, et al.
Publicado: (2017)

Epigenetics, c-Myc and Aggressive B-cell Lymphomas
por: Zhang, Yizhuo, et al.
Publicado: (2012)

Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma
por: Bartholow, Tanner L, et al.
Publicado: (2011)

c-Myc steers translation in lymphoma
por: Cargnello, Marie, et al.
Publicado: (2019)

MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma
por: Lu, Ting-Xun, et al.
Publicado: (2015)

Correlation Between C-MYC, BCL-2, and BCL-6 Protein Expression and Gene Translocation as Biomarkers in Diagnosis and Prognosis of Diffuse Large B-cell Lymphoma
por: Zhang, YunXiang, et al.
Publicado: (2019)

YL064 activates proteasomal-dependent degradation of c-Myc and synergistically enhances the anti-tumor activity of ABT-199 in diffuse large B cell lymphoma
por: Shan, Huizhuang, et al.
Publicado: (2020)

Matrine suppresses cell growth of diffuse large B-cell lymphoma via inhibiting CaMKIIγ/c-Myc/CDK6 signaling pathway
por: Gu, Jianyou, et al.
Publicado: (2021)

Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma
por: Huang, Sixia, et al.
Publicado: (2019)

A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma
por: Schuhmacher, Bianca, et al.
Publicado: (2016)

Diagnostic utility of p63/P501S double sequential immunohistochemical staining in differentiating urothelial carcinoma from prostate carcinoma
por: Srinivasan, Malini, et al.
Publicado: (2011)

Establishment and characterization of a novel MYC/BCL2 “double-hit” diffuse large B cell lymphoma cell line, RC
por: Pham, Lan V., et al.
Publicado: (2015)

A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma
por: Bosch, Mark, et al.
Publicado: (2018)

Drug-induced aneuploidy and polyploidy is a mechanism of disease relapse in MYC/BCL2-addicted diffuse large B-cell lymphoma
por: Islam, Shariful, et al.
Publicado: (2018)

BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase
por: Zou, Dehui, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_tedtr75k4bj68hevscvleubcqo